Purpose
The purpose of this paper is to focus on business responses to the pandemic through an ethical lens and to make recommendations for future research in this unique environment. The Coronavirus Disease 2019 (COVID-19) pandemic presents many ethical implications for businesses’ responses in balancing individual health and firm risks during the initial and recovery stages. What decisions are businesses making in this pandemic environment? What ethical foundations most align with these decisions?
Design/methodology/approach
The authors review recent business actions taken in response to the pandemic in light of models of motivation for corporate social responsibility (CSR).
Findings
Businesses have engaged in a wide range of philanthropic CSR actions during the pandemic, likely motivated by both utilitarianism and deontological factors in response to the needs of internal and external stakeholders. The pandemic has disparate impacts, generally hurting lower-income individuals more, likely increasing inequality.
Research limitations/implications
There are many questions for future research to determine where pandemic-related CSR has different effects for businesses over the long term compared to the pre-pandemic environment.
Social implications
Businesses must act to benefit society, protect employees and maintain the trust of their stakeholders during the pandemic.
Originality/value
Existing models have examined corporate disaster philanthropic responses that were localized and acute. Business responses to the COVID-19 virus are unique given the severity, the widespread nature and the duration of the crisis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.